Mar 04, 2020 3:10 pm EST Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company’s Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19
Mar 03, 2020 8:00 am EST Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus
Dec 16, 2019 7:00 am EST Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130
Nov 20, 2019 8:00 am EST Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients
Nov 18, 2019 8:00 am EST Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference
Nov 15, 2019 8:30 am EST Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update
Nov 11, 2019 7:00 am EST Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting
Nov 05, 2019 8:00 am EST Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment